// App-Quantinova.ai

: Impact of the Number of Years with Exacerbations During Maintenance Therapy on Lung Function Decline in COPD

Researchers

Presenter

  • M. Kerkhof

Principal Investigators

  • J. Voorham

  • C. Cabrera

  • P. Darken

  • P. Dorinsky

  • J. W. H. Kocks

  • M. Sadatsafavi

  • D. D. Sin

  • D. B. Price

Medical Centers

  • Observational and Pragmatic Research Institute, Singapore, Singapore,

  • AstraZeneca, Molndal, Sweden

  • Pearl – a member of the AstraZeneca Group and AstraZeneca, Morristown, NJ, United States.

  • Pearl, a member of the AstraZeneca Group, Durham, NC, United States,

  • The University of British Columbia, Vancouver, BC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

Disease

  • Asthma

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved